Evidence map›Paper›PMID 41824101›Full record

ArticleBreast cancer research and treatment2026

Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer.

Patrick N Song, Ameer Mansur, Carlos A Gallegos, Pragya Ghanate, Suzanne E Lapi, Anna G Sorace

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrick N SongDepartment of Radiology, The University of Alabama at Birmingham, Birmingham, USA.
Ameer MansurDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.
Carlos A GallegosDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, USA.
Pragya GhanateDepartment of Radiology, The University of Alabama at Birmingham, Birmingham, USA.
Suzanne E LapiDepartment of Radiology, The University of Alabama at Birmingham, Birmingham, USA.
Anna G SoraceDepartment of Radiology, The University of Alabama at Birmingham, Birmingham, USA. asorace@uabmc.edu.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
UAB Predoctoral Training Grant in Translational and Molecular SciencesT32GM135028 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Mythreye Karthikeyan, RAKESH P. PATEL · 2021 to 2026
$1.6M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
$1.4M
National Cancer Center R01CA240589NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA240589NCI NIH HHS R01 CA276540NIGMS NIH HHS T32 GM135028NIGMS NIH HHS T32GM135028
6 · The paper itself

Abstract

introductionTucatinib, a small molecule HER2 inhibitor, was approved in inoperable or metastatic HER2 + breast cancer. As many patients have tumors in challenging surgical locations, there is a need for imaging metrics to characterize tucatinib response and microenvironment impact. Molecular imaging can be used to quantify dynamic molecular changes that precede tumor size alterations and can target proliferation (fluorothymidine, [

methodsMice with HER2 + human cell line (BT474) or patient derived xenograft (BCM 3472) tumors were treated with 50 mg/kg tucatinib and enrolled into imaging cohorts: imaged with [

resultsTucatinib-treated human cell line and PDX tumors had significantly decreased hypoxia and proliferation relative to control tumors (p < 0.05). Tucatinib-treated BT474 tumors had significantly decreased HER2 expression (p < 0.05); however, no significant HER2 change was observed in BCM3472 tumors.

conclusionTucatinib significantly decreases intratumoral proliferation and hypoxia in both cell-line and patient-derived xenograft models of HER2 + breast cancer, which can be longitudinally quantified with PET imaging. Our data suggests molecular imaging may improve understanding and prediction of tucatinib response.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesMolecular ImagingPyridinesQuinazolinesTriazolesTumor MicroenvironmentAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalFemaleHumansMiceOxazolesPositron-Emission TomographyERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOxazolesPyridinesQuinazolinesTriazolestucatinib[89Zr]Zr-PertuzumabBCM3472BT474FLTFMISOPETPositron emission tomographySmall molecule inhibitor

Identifiers

PMID41824101
PMCPMC12987860

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.